Familial autoinflammatory diseases: genetics, pathogenesis and treatment
Silvia Stojanov and Daniel L. Kastner

Purpose of review
The systemic autoinflammatory diseases are characterized by seemingly unprovoked inflammation, without major involvement of the adaptive immune system. This review focuses mainly on a subset of these illnesses, the hereditary recurrent fevers, which include familial Mediterranean fever, the tumor necrosis factor receptor-associated periodic syndrome, the hyperimmunoglobulinemia D with periodic fever syndrome, and cryopyrin-associated periodic syndromes. This review elucidates how recent advances have impacted diagnosis, pathogenesis, and treatment.

Recent findings
More than 170 mutations have been identified in the four genes underlying the six hereditary recurrent fevers. Genetic testing has broadened the clinical and geographic boundaries of these illnesses, given rise to the concept of the cryopyrin-associated periodic syndromes as a disease spectrum, and permitted diagnosis of compound heterozygotes for mutations in two different hereditary recurrent fever genes. Genetics has also advanced our understanding of amyloidosis, a complication of the hereditary recurrent fevers, and suggested a possible role for common hereditary recurrent fever variants in other inflammatory conditions. Recent advances in molecular pathophysiology include the elucidation of the N-terminal PYRIN domain in protein-protein interactions, the description of the NALP3 (cryopyrin) inflammasome as a macromolecular complex for interleukin-1β activation, and the identification of signaling defects other than defective receptor shedding in patients with tumor necrosis factor receptor-associated periodic syndrome. These molecular insights form the conceptual basis for targeted biologic therapies.

Summary
Advances in molecular genetics extend our ability to recognize and treat patients with systemic autoinflammatory diseases and inform our understanding of the regulation of innate immunity in humans.

Keywords
genetics, hereditary recurrent fevers, inflammasome, systemic autoinflammatory diseases, therapy

Introduction
The concept of autoinflammatory disease was first proposed in 1999 to describe a group of inherited disorders characterized by episodes of seemingly unprovoked inflammation that, in contrast to the traditionally defined autoimmune diseases, lack high-titer autoantibodies or antigen-specific T-cells [1]. Two hereditary recurrent fevers (HRFs), familial Mediterranean fever (FMF; Mendelian inheritance in man [MIM] 249100) and the then newly recognized tumor necrosis factor receptor-associated periodic syndrome (TRAPS, MIM 142680), were the prototypes for this diagnostic category. The following year, this concept was extended to subsume several mendelian disorders, including other HRFs, the familial urticarial disorders (now included among the HRFs), familial Mediterranean fever, pyogenic arthritis with pyoderma gangrenosum and acne (PAPA) syndrome, the hyperimmunoglobulinemia D with periodic fever syndrome (MIM 178500), were also included among the proposed autoinflammatory diseases, and it seems reasonable to suggest that some apparently acquired disorders of inflammation, such as the syndrome of periodic fever with aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) [3], may also properly fall under this rubric.

Subsequent advances in molecular genetics have vindicated the notion of autoinflammatory disease as a unifying concept, at both the structural and functional levels [4].
| Characteristics of the hereditary recurrent fevers and the autoinflammatory PAPA syndrome |
|---------------------------------|--------|--------|--------|--------|--------|--------|
| Inheritance                    | FMF    | HIDS   | TRAPS  | FCAS   | MWS    | NOMID/CINCA |
| Gene                           | Recessive | Recessive | Dominant | Dominant | Dominant | Dominant/de novo |
| Chromosome                     | 16p13  | 12q24  | 12p13  | 1q44   | 15q24  | 15q24 |
| Protein                        | MEFV   | MVK    | TNFRSF1A | CD2BP1/PSTPIP1 | CIAS1/NALP3/PYPAF1 | CD2BP1/PSTPIP1 |
| Expression                     | Granulocytes, monocytes, synovial fibroblasts | Increased IL-1β and NF-κB activation, impaired leukocyte apoptosis | Temperature-dependent MK activity causes a deficiency in isoprenoid products, leading to increased IL-1β secretion and/or increased mevalonate may induce inflammation | Increased activity of the NALP3/Cryopyrin inflammasome with subsequent IL-1β secretion and NF-κB activation | Mutations cause increased PSTPIP1 binding to pyrin, leading to increased IL-1β secretion |
| Proposed pathogenesis          |        |        |        |        |        |        |
| Classical features             |        |        |        |        |        |        |
| Ethnicity                      | Jewish, Armenian, Arab, Turkish, Italian | Dutch, French, other European | Any ethnic group | Mostly European | Northern European | Any ethnic group |
| Duration of episodes           | 1–3 days | 3–7 days | Often >1 week | Usually <24 hours | 24–48 hours | Almost continuous, with exacerbations |
| Distinguishing clinical findings | Polyserositis, erysipelas erythema, monoarthritis, splenomegaly, constipation | Cervical lymphadenopathy, headache, elevated urinary mevalonate during attacks, reduced MK activity in between attacks | Periorbital edema, migratory nature of myalgia and rash | Cold-induced urticaria-like rash | Sensorineural hearing loss | Onset of urticarial rash in infancy, chronic aseptic meningitis, sensorineural hearing loss, arthropathy |
| Amyloidosis                    | Common | Very rare | −10% of cases | Uncommon | Reported in 25% of cases | Reported in a minority of patients who reach adulthood |

PAPA, pyogenic arthritis with pyoderma gangrenosum and acne; FMF, familial Mediterranean fever; HIDS, hyperimmunoglobulinemia D with periodic fever syndrome; TRAPS, tumor necrosis factor receptor-associated periodic syndrome; FCAS, familial cold autoinflammatory syndrome; MWS, Muckle–Wells syndrome; NOMID/CINCA, neonatal-onset multisystem inflammatory disease/chronic infantile neurologic cutaneous and articular syndrome; −, approximately; MK, Mevalonate kinase.
This is particularly well illustrated among the HRFs, salient genetic and clinical features of which are summarized in Table 1. FMF, the most common and probably most thoroughly studied HRF, is caused by mutations in MEFV, encoding the pyrin/marenostrin protein [5,6]. Mutations in the related protein cryopyrin (alternatively called NALP3 because it belongs to a family of proteins containing a NACHT domain, leucine-rich repeat, and PYRIN domain) or PYPAF1 give rise to the so-called cryopyrin-associated periodic syndromes (CAPS): familial cold autoinflammatory syndrome (FCAS, MIM 120100), Muckle–Wells syndrome (MWS, MIM 191900), and neonatal-onset multisystem inflammatory disease (NOMID, also called chronic infantile neurologic cutaneous and articular syndrome or CINCA, MIM 607115) [7–9]. Both pyrin and cryopyrin share an N-terminal motif, the PYRIN domain, that facilitates cognate protein-protein interactions (reviewed by Kastner and Aksentijevich [10**]). The PYRIN domain is, in turn, a member of a larger family of protein motifs, the death domain-fold superfamily [11]. Another member of this superfamily, the death domain, is found at the N-terminus of the protein mutated in TRAPS, the p55 TNF receptor (TNFRSF1A) [1]. As discussed here, through their respective PYRIN and death domains, cryopyrin, pyrin, and the p55 TNF receptor play an important role in regulating cytokine secretion, nuclear factor-kB activation, and apoptosis, and thereby the innate immune system.

Although the gene mutated in the hyperimmunoglobulinemia D with periodic fever syndrome (HIDS, MIM 260920) [12,13] does not encode such a motif, recent data suggest that it may also impinge on the innate immune system through the regulation of interleukin-1β secretion. There are also structural and functional relationships between the HRF proteins and the proteins mutated in several other autoinflammatory disorders, including Blau’s syndrome and the syndrome of pyogenic arthritis with pyoderma gangrenosum and acne (PAPA, MIM 604416).

Increased awareness of the systemic autoinflammatory diseases, coupled with the widespread availability of genetic testing, has catalyzed the evolution of our concepts of diagnosis, genotype-phenotype interaction, and the broader role of the causative genes and proteins in health and disease, while concomitant advances in our understanding of pathophysiology have allowed dramatic breakthroughs in targeted biologic therapy. This review focuses on significant advances of the past year.

**Clinical genetics**

Although no new HRF genes have been identified over the past year, mutational studies of cohorts of affected patients have substantially advanced our understanding of the biologic role of the relevant genes and proteins. Areas of progress include refinement of the relationships between gene mutations and specific disease-associated clinical manifestations; analysis of the role of specific mutations and modifier factors in the risk of amyloidosis; and delineation of the relation between common gene variants and the broader spectrum of inflammatory disease.

**Population genetics and genotype-phenotype relationships**

Given the relative accessibility of DNA diagnostics and the absence of reliable biochemical markers for FMF, TRAPS, and CAPS, genetic testing has become an important adjunct in the diagnosis of the HRFs. The growing list of mutations and polymorphisms of these mendelian disorders is frequently updated in INFEVERS [14*], a mutational database accessible on the World Wide Web at http://fmf.igh.cnrs.fr/infevers. To date more than 50 disease-associated mutations are listed for FMF, more than 40 for TRAPS, more than 35 for CAPS, and more than 30 for HIDS. It is interesting to note that, among HRF-associated mutations, nearly all are missense mutations, and, with two exceptions in FMF, nearly all spare the death domain-fold motif, where present, in the respective HRF proteins.

Implementation of genetic screening has extended the diagnosis of specific HRFs to a wider range of ethnicities than originally appreciated. The recognition of FMF among Greeks, Italians, and some non-Mediterranean populations [15*] and of TRAPS in an even more global distribution [16] is already established. A recent report from Italy extends the geographic distribution of HIDS, formerly regarded as occurring primarily in individuals of northern European ancestry, to the south, with a total of 14 mutation-positive cases from Italy and Albania [17**].

Several recent reports also address specific mutations in HRF genes. A Spanish group has reported a novel H478Y MEFV variant associated with prolonged fevers, predominant joint involvement, colchicine resistance, and an autosomal dominant mode of inheritance in a three-generation family [18*]. This severe MEFV variant joins two others, ΔM694V and the M694I-E148Q complex allele, with an apparent dominant inheritance [19]. Perhaps at the opposite end of the spectrum of severity is the MEFV variant E148Q, which is present at sufficiently high frequency in several Middle Eastern control populations to be considered a low-penetrance variant [20] or perhaps even a benign polymorphism [21]. A recent Turkish series reported clinical features on 26 individuals homozygous for E148Q, all but four of whom were symptomatic [22*]. With the reservation that these patients did not undergo complete MEFV sequencing, and therefore could possibly harbor other unknown mutations, E148Q homozygotes had a distribution of symptoms similar to that of patients with other FMF-associated genotypes and a similar
responsiveness to colchicine. These data suggest that, at least under certain as-yet undefined genetic and environmental conditions, this $MEFV$ variant may be associated with the FMF phenotype.

Especially in the case of TRAPS, recent publications point to a possible broadening of the clinical phenotype. The question of neurologic involvement in TRAPS has been raised in several case reports, including the description of one woman with the T50K $TNFRSF1A$ mutation with abnormal findings on magnetic resonance imaging [23**], although the causal relation is not completely clear due to concomitant etanercept treatment. A second paper reported panniculitis in individuals with the T50M and R92Q mutations [24•]. A third report presented the case of an African American boy with the P46L $TNFRSF1A$ variant and myocarditis and sacroiliitis, two previously unrecognized manifestations of TRAPS [25••]. Although P46L is the only $TNFRSF1A$ variant that we have seen among African American TRAPS patients in our clinic, it should be noted that it is also seen in approximately 4% of African American control individuals [26], and in an even higher percentage of west African controls [27••], indicating that P46L is frequently not fully penetrant, at least for the TRAPS phenotype.

Considerable recent attention has also been focused on mutations in $CIAS1$, which can cause FCAS, MWS, and the NOMID/CINCA syndrome. According to accepted clinical definitions, FCAS is characterized by cold-induced episodes of fever and urticarial skin rash, without evidence of hearing impairment [28••]. MWS presents with febrile episodes not necessarily induced by cold, but often with sensorineural hearing loss and systemic amyloidosis [10**]. NOMID/CINCA manifests urticarial rash regardless of temperature, with central nervous system involvement (papilledema, cerebrospinal fluid pleiocytosis, or sensorineural hearing loss) and a characteristic arthropathy [29•]. Recent case reports and clinical series confirm earlier impressions of a more continuous spectrum of phenotypes [30–32], including MWS patients with features of FCAS [33•], families in which multiple members exhibit manifestations of FCAS, MWS, or NOMID/CINCA [34••,35•], and patients with unique variant phenotypes [36••], one of which is associated with the first mutation to be described in the cryopyrin leucine-rich repeat (LRR) domain [37••]. Moreover, several mutations have been identified in both FCAS and MWS [7,29••,38,39,40••] and in both MWS and NOMID [8,9,29••,32,38,40••,41].

Genetic screening for mutations in the HRF genes has also revealed the coexistence of mutations of two different autoinflammatory disease genes in a single subject. In one case, a 7-year-old girl was found to have the V377I mutation at the HIDS-associated mevalonate kinase ($MVK$) locus, as well as the R92Q variant at $TNFRSF1A$, and presented with mild features of HIDS but responded to steroids in a way more characteristic of TRAPS [42••]. A second patient with compound heterozygosity for V377I/S378P $MVK$ was also found to have the R92Q $TNFRSF1A$ variant and manifested disproportionately severe biochemical mevalonate kinase deficiency relative to her mild clinical phenotype [43••]. Another patient with V377I and G211A mutations in $MVK$ and the P46L $TNFRSF1A$ variant had more severe symptoms that partially responded to the TNF inhibitor etanercept [44]. Yet another patient of Chinese ancestry with prolonged episodes of fever and abdominal pain was found to have compound heterozygosity for the Y20D $TNFRSF1A$ mutation and the E148Q variant of $MEFV$ [45••]. Given the relatively high frequency of R92Q in the white population [26] and E148Q in the Chinese [46], it is not altogether surprising that compound heterozygosity involving these variants would be observed. Longitudinal follow-up over many years may be needed to define the phenotypic ramifications of these gene interactions.

Several important questions in the genetics of the HRFs must be resolved. Substantial numbers of patients meeting clinical criteria for FMF, HIDS, or the cryopyrinopathies, or who have clinical features resembling TRAPS, do not have demonstrable mutations at any of the known causative genes. Although noncoding mutations remain a logical possibility, it is also possible that there are additional HRF genes yet to be found. A second major area of interest is defining the factors affecting penetrance. Population-based estimates of the frequency of $MEFV$ mutations among several ethnic groups [10**], of the V377I mutation in $MVK$ in the Netherlands [47], and of the R92Q [26] and P46L [27••] variants of $TNFRSF1A$ in whites and African Americans, respectively, all point to the likelihood of reduced penetrance of the respective mutations. Finally, for the case of the recessively inherited FMF, it remains a puzzle why as many as one third of patients with clinical disease have only one demonstrable mutation [10**]. The answer to this latter question may be tied to the resolution of the first two.

**Amyloidosis in the hereditary recurrent fevers**

Systemic amyloidosis is one of the most serious manifestations of the HRFs and is the result of the tissue deposition of misfolded fragments of serum amyloid A (SAA), one of the acute-phase reactants produced by the liver in response to systemic inflammation [48]. Most frequently, deposition occurs in the kidneys, gastrointestinal tract, adrenals, spleen, testes, and lung and sometimes in the liver, heart, and thyroid. In the precolchicine era, amyloidosis was a frequent cause of death in patients with FMF, particularly north African Jews, Turks, and Armenians. Amyloidosis in FMF can sometimes precede the development of febrile attacks (phenotype II), a phenomenon that
is probably due to the persistent subclinical inflammatory state seen even in the absence of symptoms in some HRF patients [16,49–52,53,54].

A substantial body of literature indicates an increased risk for amyloidosis among Jewish, Arab, and Armenian patients who are homozygous for the M694V mutation [55–59]. In a series of more than 1000 Turkish patients for whom mutational analysis was available [60], however, there was no statistically significant association between this genotype and the risk of amyloidosis. Although other smaller series from Turkey have come to the same conclusion [61,62], the explanation for the difference from other populations is not clear but could involve either differences in the frequency of modifier genes or environmental effects.

One apparently important modifier factor in amyloidosis risk in FMF is the SAA1 precursor isoform, with the α/α variant conferring increased risk [63,64]. In a recent series from Turkey, seven of 23 FMF patients with this genotype had amyloidosis vs one of 51 patients with other SAA1 genotypes [65]. Significant differences were also observed in a recent study of 70 Arab patients [66]. The mechanism by which this SAA1 variant increases amyloid risk is unknown, but current speculation focuses on differences in macrophage processing or intrinsic potential for fibril formation [63].

Amyloidosis also occurs relatively frequently in patients with MWS and NOMID/CINCA, as well as TRAPS. In TRAPS, susceptibility to amyloidosis appears to be increased among patients with mutations at cysteine residues [26], although patients with noncysteine mutations, most notably T50M, have been reported [67]. Amyloidosis is extremely rare in HIDS, with the first case having been reported only within the past year [68]. It is not clear whether the rarity of amyloidosis in HIDS, relative to FMF, TRAPS, MWS, and NOMID/CINCA, is due to an overall lower SAA burden in HIDS, to less amyloidogenic alleles at modifier genes, or to environmental factors.

Role of hereditary recurrent fever genes in inflammation

Given the relatively high frequency of certain HRF alleles in the general population, there has been considerable speculation that some of these variants may also predispose to other inflammatory phenotypes [26]. It goes without saying that in situations such as this, in which common genetic variants of HRF genes are sought in other relatively common illnesses, controls that are appropriately matched, particularly for ethnic background, are essential. Particularly striking are the results of a study of the R92Q variant in a large European study of cardiovascular disease [69]. Among 62 cigarette smokers with carotid plaque, 9.7% had R92Q, vs 2.1% of 338 smokers without plaque, for an odds ratio of 5.97 (95% confidence interval 1.64–15.63, \( P = 0.0048 \)). Other less dramatic associations were also noted between R92Q and carotid intima-media thickness. R92Q and the E148Q MEFV variant have also been recently associated with increased susceptibility for reactive systemic AA amyloidosis in other chronic inflammatory disorders [70].

Two studies have noted an increased incidence of Crohn’s disease in patients or families with FMF [71,72]. Recently, another investigative group examined the frequency of MEFV mutations in a cohort of 209 Israeli patients with Crohn’s disease [73]. In this study, there was no increase in the frequency of specific MEFV mutations in cases relative to controls, although the E148Q variant was associated with perianal disease, with an odds ratio of 3.26 (95% confidence interval 1.2–8.8, \( P = 0.02 \)).

Finally, associations have been drawn between FMF and Behçet’s disease. Increased frequencies of MEFV mutations have been reported in Behçet’s patients [74], and, conversely, Behçet’s disease has been reported at an increased frequency among Israeli patients with FMF [75]. A recent paper from Turkey found MEFV mutations in 15 of 42 Behçet’s patients, but in only seven of 66 controls (\( P = 0.0034 \)) [76].

Although the HRF genes may, in some circumstances, conspire with other genetic and environmental factors to cause a broader spectrum of inflammatory diseases, certain disorders may actually be less common in the HRFs. Recently a group from Turkey drew attention to the complete absence of systemic lupus erythematosus among their cohort of more than 1000 FMF patients [77]. The authors speculated that high levels of C-reactive protein typically seen in FMF patients might increase clearance of apoptotic cells and autoantigens. Although this remains an intriguing hypothesis, it underscores the potentially complicated and even reciprocal interactions among autoinflammatory and autoimmune disorders, which represent respective aberrations of the innate and adaptive arms of the immune system. The suggestion of a possible positive correlation between systemic lupus erythematosus and TRAPS in the Japanese population [78] awaits confirmation.

Pathogenesis

The elucidation of the molecular basis of the HRFs has focused attention on a group of genes encoding proteins (Fig. 1) that regulate several critical inflammatory and apoptotic pathways. Much of the past 2 to 3 years’ work has concentrated on further delineating these pathways and understanding how specific disease-associated genes cause autoinflammation.
Pyrin and family
Signal transduction and protein oligomerization in inflammation and apoptosis are often mediated by a group of protein-protein interaction domains, the so-called death domain-fold superfamily [11]. This family currently comprises four members, the death domain, the death effector domain, the caspase-recruitment domain (CARD), and the PYRIN domain. Each motif has an antiparallel arrangement of six α-helices that allows binding of cognate domains (death domains with death domains, etc.) through electrostatic charge interactions [11,79–81].

The pyrin protein is the prototype for the death domain-fold motif that bears its name. The recognition of the PYRIN domain, an N-terminal 92-amino-acid motif, in pyrin set the crucial cornerstone for further insights into the underlying mechanisms of the HRFs. Of the approximately 20 PYRIN domain-containing human proteins currently known [82••], pyrin and cryopyrin have been shown to harbor HRF-associated mutations. A third member of this family, apoptosis-associated specklike protein with a CARD (ASC), is a bipartite adaptor protein consisting of an N-terminal PYRIN domain, through which it can interact with pyrin [79,83–85] or cryopyrin [84,86,87], and
a C-terminal CARD, through which it can interact with several downstream molecules. Although no disease-associated ASC mutations have been identified in HRF patients to date, it is a pivotal molecule in the pathogenesis of these diseases.

Recent biochemical evidence indicates that cryopyrin (NALP3) and ASC participate in a larger macromolecular complex termed the NALP3 inflammasome [88**,89**] that mediates the activation of interleukin-1β and interleukin-18. The NALP3 inflammasome activates interleukin-1β by bringing molecules of caspase-1 (interleukin-1β-converting enzyme) zymogen into proximity, thus allowing autocatalysis of its p20 and p10 subunits, which, when released, cleave prointerleukin-1β into its biologically active form. As depicted in Figure 2, interaction of the LRR domain of cryopyrin/NALP3 with the NACHT domain (so named because it was first observed in neuronal apoptosis inhibitor protein, CIITA, HET-E and TP1) ordinarily inhibits the interaction of cryopyrin/NALP3 with Cardinal, another protein in the complex. Stimuli that ‘open’ the cryopyrin/NALP3 structure permit this interaction, through which one molecule of caspase-1 is recruited to the complex. A second caspase-1 molecule is recruited through the interaction of the PYRIN domain of cryopyrin/NALP3 with ASC.

From the foregoing analysis, it would appear that the LRR – NACHT domain interaction in cryopyrin/NALP3 is a critical control point in the activation of the inflammasome. Just as extracellular LRRs of the Toll-like receptors can interact with various pathogen-associated molecular patterns, intracellular muramyl dipeptide, a common pathogen-associated molecular pattern, can activate the NALP3/cryopyrin inflammasome [89**], presumably by binding the LRR. CAPS-associated mutations are almost exclusively in the NACHT domain, and macrophages from a patient with MWS showed increased interleukin-1β secretion in the presence of muramyl dipeptide. In some cases, CAPS-associated cryopyrin/NALP3 mutations may even permit constitutive interleukin-1β maturation [88**,90**,91†] without the requirement for exogenous muramyl dipeptide. It is also possible, although not proven, that FCAS-associated cryopyrin/NALP3 mutations destabilize the NACHT-LRR interaction in the cold, thereby permitting interleukin-1β activation.

Pyrin itself also appears to play an important role in regulating interleukin-1β activation. In-vitro data suggest that pyrin competes with both cryopyrin and caspase-1 for binding to ASC [83,84]. Mice expressing a truncated, hypomorphic pyrin variant exhibit heightened sensitivity to endotoxin challenge, with increased activation of both caspase-1 and interleukin-1β. These data suggest that one function of wild-type pyrin is the suppression of inflammasome-mediated interleukin-1β production and that FMF-associated mutations may interfere with this process (Chae et al., unpublished observations). Mutations in proline serine threonine phosphatase interacting protein 1 (PSTPIP1), a protein recently shown to bind pyrin, appear to exert a dominant negative effect on this pathway [92]. Two PSTPIP1 mutations (Fig. 1) have been associated

---

**Figure 2. Schematic of the molecular mechanisms defining the cryopyrin (NALP3) inflammasome**

The grey area shows the macromolecular complex that forms the cryopyrin (NALP3) inflammasome. The main function of this complex is the proximity-induced autocatalysis of pro-caspase-1 to active caspase-1, with subsequent IL-1β activation. Pyrin is thought to have an inhibitory effect on this process, while mutations in CD2BP1/PSTPIP1 may interfere with the normal action of pyrin. Details of the interactions are discussed in the text. Arrows indicate the induced interactions between functional protein domains. The inhibitory effects of CD2BP1/PSTPIP1 and pyrin, respectively, are marked as lines with a short ‘blocking’ line at the end.
with increased pyrin binding, excessive interleukin-1β production, and a severe autoinflammatory disorder, the PAPA syndrome.

Both cryopyrin and pyrin also appear to regulate another process important in inflammation: apoptosis. The aforementioned pyrin-deficient mice exhibit a defect in leukocyte apoptosis through an interleukin-1β-independent, caspase-8-dependent pathway [83], suggesting a proapoptotic role for the wild-type protein, although in certain transfection systems it exerts an antiapoptotic effect [79,84,85]. Enforced expression of cryopyrin in HEK293T cells also induces apoptosis [84].

Depending on the cellular context, both pyrin and cryopyrin can either activate or suppress nuclear factor-κB [84,86,87,93,94], a family of transcription factors involved in the initiation and resolution of inflammation. Although the precise mechanism is still under investigation, this appears to be ASC dependent and, under some conditions, involve the inhibitor of nuclear factor-κB kinase complex [93]. Because endogenous pyrin has recently been shown to localize in the nucleus in several cell types, including synovial fibroblasts, neutrophils, and dendritic cells (but not monocytes) [95,96], it is also possible that pyrin may associate with one or more components of the nuclear factor-κB complex. Moreover, in the absence of ASC, a relatively rare isofrom of pyrin with an inframe deletion of exon 2 also localizes in the nucleus, regardless of FMF-associated mutations [96].

**TRAPS: the plot thickens**

Stimulation through the p55 TNF receptor can lead either to nuclear factor-κB activation or apoptosis, depending on the balance of several contextual factors. Upon receptor activation through TNF, metalloprotease-induced cleavage of the extracellular TNFRSF1A domain can limit continuous signaling at the cell surface while simultaneously creating a pool of potentially antagonistic soluble receptor (Fig. 3A). Initial studies of a family with the C52F mutation indicated impaired activation-induced receptor ‘shedding’ [1], thereby possibly explaining the inflammatory phenotype.

Subsequent studies indicate a more complex picture, with defects in TNF receptor cleavage varying with mutation [26,97] and cell type [98,99]. Moreover, in transfection experiments, certain TNFRSF1A mutants exhibit impaired intracellular trafficking and TNF binding, although their ability to signal through the death domain is unimpaired [99,100]. Conceivably, the conformational changes in the p55 receptor that lead to altered intracellular trafficking could also impair metalloprotease-induced cleavage of mutant receptors that do reach the surface. Studies of dermal fibroblasts and monocytes from a patient with the newly identified C43S mutation suggest yet another possible mechanism for TRAPS: a defect in TNF-induced apoptosis, leading to an inappropriately prolonged inflammatory response [100].

TRAPS-associated p55 mutations might also cause constitutive activation, perhaps by permitting intermolecular disulfide homodimerization and ligand-independent activation. This possibility was considered for patients with the C52F mutation in the initial description of TRAPS but appeared not to be operative [1]. Moreover, such a mechanism would appear to be inconsistent with the therapeutic effects of TNF inhibitors (vide infra). It may be fruitful, however, to reexamine this issue for a broader sampling of patients, given the heterogeneity of cleavage defects for different mutations, the observation of biochemical inflammation in TRAPS patients even between attacks [16], and the discovery of ligand-independent noncovalent interactions mediated by the first cysteine-rich domain of the p55 receptor [101]. Yet another conceptually attractive possibility relates to the recent finding that the predominant form of TNFRSF1A in human plasma is full length, probably the result of exosome-linked release of receptor [102]. In light of the aforementioned defects in receptor trafficking, it is intriguing to hypothesize that TRAPS mutations might impair such a process.

From the foregoing, it appears clear that there may be multiple mechanisms leading to the TRAPS phenotype and that the pathophysiology may be heterogeneous among patients. Clarification of these issues will undoubtedly require triangulation between studies of primary cells from patients, transfected cell lines, and knock-in animal models.

**Hyperimmunoglobulinemia D with periodic fever syndrome: nature’s elaborate deception?**

Perhaps the most enigmatic of the HRFs is HIDS. The enzyme mutated in HIDS, called mevalonate kinase, is the only HRF protein that does not include a death domain motif. Mevalonate kinase catalyzes the conversion of mevalonic acid to 5-phosphomevalonic acid in the synthesis of sterols, including cholesterol, vitamin D, bile acids, and steroid hormones (Fig. 3B). Evidence is strong that HIDS is not due to excessive IgD, because there are well-documented patients who have the HIDS phenotype and MVK mutations but persistently normal IgD levels [12,103–105], and, even among patients with increased serum IgD, the levels do not predictably fluctuate with attacks [106]. Moreover, the HIDS phenotype appears not to be due to a defect in cholesterol synthesis, because patients have cholesterol levels in the low-normal range, and more severe disorders of cholesterol biosynthesis do not have an autoinflammatory phenotype [107].

Currently there are two major hypotheses on the pathogenesis of HIDS: that the inflammatory attacks could result from the accumulation of mevalonic acid, the
substrate for the mevalonate kinase enzyme [108*], or that the autoinflammation is caused by a shortage of isoprenoids, which are normally synthesized through the mevalonate pathway [109]. These latter compounds are involved in the post-translational prenylation (farnesylation or geranylation) of several important intracellular signaling molecules, including the Ras, Rho/Rac, and Rab families of small guanosine triphosphate-binding proteins. In an in-vitro system, accentuated interleukin-1β secretion by leukocytes from HIDS patients can be reversed by the addition of farnesol or geranyl-geraniol, lending support to the second hypothesis [109].

Both the isoprenoid deficiency and mevalonate accumulation hypotheses predict a worsening of symptoms with decreased mevalonate kinase enzymatic activity. In-vitro studies of cell lines harboring wild-type or HIDS-mutant MVK indicate that the mutant enzyme functions best at 30°C, with a diminution at 37°C and further decreases at 39°C [110]. This finding may account for the triggering
of HIDS attacks by immunizations and infections and may also account for the increased urinary mevalonate levels seen during HIDS attacks.

**Treatment**

Advances in our understanding of the biology of HRFs, coupled with the expanded armamentarium of new targeted therapies, have led to new approaches to the treatment of these disorders. Therapeutic goals include suppression of acute attacks, which are usually not life threatening but can be very disabling, and preventing long-term sequelae, such as amyloidosis and long-term neurologic/intellectual impairment in CAPS.

The most promising results of the past year involve the use of anakinra, a recombinant human interleukin-1\(\beta\) receptor antagonist, in patients with CAPS. FCAS patients who were pretreated with interleukin-1\(\beta\) receptor antagonist before cold challenge did not develop clinical symptoms or increase in acute-phase reactants [111\*]. Serum levels of interleukin-1\(\beta\) and cytokine mRNA in peripheral blood mononuclear cells were normal but highly elevated in affected parts of the skin, implicating differences in the distribution of cells contributing to disease phenotype. A complete cessation of clinical symptoms and biochemical changes was also reported in MWS patients following administration of interleukin-1\(\beta\) receptor antagonist [112,113\*]. Even children with the more severe phenotype of NOMID/CINCA responded to anakinra doses of 1–2 mg/kg per day with resolution of uveitis, rash, and fever and a significant decline in cerebrospinal fluid pressure [114\*–117\*]. The dramatic nature of the response of CAPS patients to interleukin-1 inhibition is, in a way, surprising, given the apparent role of cryopyrin in other inflammatory processes, such as nuclear factor-\(\kappa\)B activation and apoptosis. Given the reduced life expectancy of NOMID/CINCA patients, who have a death rate of about 20\% before the age of 20, it will be important to follow a larger series of these children on anakinra to monitor long-term outcome with regard to mental and physical development, as well as to determine whether early treatment can prevent joint deformities.

As noted in the previous section, interleukin-1\(\beta\) also appears to play a role in the pathogenesis of FMF, PAPA syndrome, and HIDS and may also be involved indirectly in the pathogenesis of TRAPS. Interleukin-1 inhibition could therefore represent a possible option as first-line or second-line treatment in these diseases. Anakinra has been reported effective in the treatment of one patient each with TRAPS and PAPA syndrome [118\*,119\*].

There is also a substantial experience with TNF inhibitors in the HRFs, most notably the use of etanercept, the p75 TNFR:Fc fusion protein, in TRAPS. The administration of 50–75 mg per week in adults, or 0.8–1.2 mg/kg/wk in children, is effective in reducing, although not usually eliminating, clinical and laboratory evidence of inflammation [4,16], thereby allowing a dose reduction in nonsteroidal anti-inflammatory drugs or glucocorticoids. In some patients, etanercept appears to prevent amyloid formation or even reduce proteinuria in patients with amyloid nephropathy [120,121\*]. Unfortunately, development of amyloidosis can occur even when symptoms are controlled by etanercept [122], and it is likely that monitoring of SAA levels is necessary to titrate the optimal dosage [120,121\*].

Although HIDS very rarely leads to systemic amyloidosis, and does not share the neurologic sequelae of CAPS, attacks are frequently severe enough to warrant treatment, particularly in childhood and adolescence. To date there is no accepted therapy for HIDS, other than antipyretics and palliative measures, but pilot studies have been conducted in two areas. First, a small trial has been conducted with simvastatin, an inhibitor of 3’-hydroxy-3’-methylglutaryl – coenzyme A reductase, the enzyme immediately preceding mevalonate kinase in the mevalonate pathway (Fig. 3B). It appears safe, and preliminary data suggest a possible benefit [108\*]. A pilot study of etanercept showed substantial symptomatic improvement in two mutation-positive children with HIDS [105], although a third HIDS patient who did not respond to etanercept was recently reported by another group [123]. Interleukin-1 inhibition may represent yet another possible therapeutic strategy.

Daily oral colchicine therapy has been established as effective in preventing both the acute attacks of FMF and the development of amyloidosis. In the subset of patients who are poorly responsive to colchicine, lower colchicine concentrations were found in mononuclear cells [124\*], suggesting that differences in responsiveness may be due to polymorphisms in transporters that control intracellular drug concentrations, such as the \(MDR-1\)-encoded P-glycoprotein pump. In such patients, several adjunctive approaches are under investigation, including subcutaneous interferon-\(\alpha\) [125,126\*,127\*] and biologic therapies aimed at TNF [128\*] or interleukin-1\(\beta\). Allogeneic bone marrow transplantation has recently been proposed as a treatment for refractory FMF [129], based on the predominant expression of \(MEFV\) in leukocytes [5]. Although it is possible that this approach could be effective, in nearly all cases other options exist, and the risks outweigh the potential benefits [130].

**Conclusion**

Identification of the genes mutated in the HRFs has led to great strides in our approach to patients with these disorders. Although substantial numbers of patients with clinical recurrent fever syndromes do not have mutations in the respective genes, the availability of genetic testing as an adjunct has led to more widespread and earlier
recognition of these conditions, and recognition of important pathogenic and therapeutic differences among patients who, 10 years ago, were largely lumped together as FMF variants. Exciting advances in molecular biology have defined new families of motifs and proteins relevant to inflammation and apoptosis, but important questions remain regarding the role of the products of the mevalonate pathway. Perhaps most notable are the great strides in therapy brought about by the happy confluence of breakthroughs in molecular pathogenesis and the new availability of targeted biologic agents. Fascinating areas for further investigation include the possible identification of additional genes that might account for patients who are currently mutation negative, the elucidation of modifier genes, the more thorough understanding of molecular pathogenesis and mechanisms of specific mutations, and a careful comparative analysis of various available treatments in multicenter trials.

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

• of special interest
•• of outstanding interest

McDermott MF, Akseintjiev I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97:133—144.

Galon J, Akseintjiev I, McDermott MF, et al. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 2000; 12:479—488.

Marshall GS, Edwards KM, Buller J, et al. Syndrome of periodic fever, pharyngitis, and aphthous stomatitis. J Pediatr 1987; 111:43—46.

Hull KM, Shoahm N, Chae JJ, et al. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol 2003; 15:61—69.

International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997; 90:797—807.

French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17:23—31.

Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29:301—305.

Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002; 70:188—203.

Akseintjiev I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cyto kinase activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46:3340—3348.

Kastner DL, Akseintjiev I. Intermittent and periodic arthritis syndromes. In: Koopman WJ, Mooreland LW, editors. Arthritis and allied conditions, 15th ed. Philadelphia: Lippincott Williams and Wilkins; 2005. pp. 1411—1461.

A very comprehensive current review of the HRFs.

Fairbrother WJ, Gordon NC, Humke EW, et al. The PYRIN domain: a member of the death domain-fold superfamily. Protein Sci 2001; 10:1911—1918.

Houten SM, Kus W, Duran M, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinemia D and periodic fever syndrome. Nat Genet 1999; 22:175—177.

Dreth JP, Cuislet L, Gradeau G, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. Nat Genet 1999; 22:178—181.

Toulou I, Lesage S, McDermott M, et al. Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum Mutat 2004; 24:194—198.

Updated information about the online database INFEVERS, a platform for report of mutations associated with autoinflammatory diseases.

Kotone-Miyahara Y, Takaori-Kondo A, Fukunaga K, et al. E148Q/M694I mutations in 3 Japanese patients with familial Mediterranean fever. Int J Hematol 2004; 79:235—237.

This paper suggests that FMF may be more frequent in Japan than previously believed.

Hull KM, Drewe E, Akseintjiev I, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002; 81:349—368.

D’Ousdal A, Picco P, Caroli F, et al. MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever. Eur J Hum Genet 2005; 13:314—320.

This thorough paper extends the geographic distribution of HIDS to Italy and describes several new mutations and clinical phenotypes.

Aldea A, Campistol JM, Arosteegui J, et al. A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEVF H478V variant in a Spanish kindred: an unusual familial Mediterranean fever phenotype or another MEVF-associated periodic inflammatory disorder? Am J Med Genet 2004; 127A:74—73.

An interesting clinical report describing a new dominantly inherited MEVF variant associated with a severe phenotype.

Booth DR, Gillmor JD, Lachmann HJ, et al. The genetic basis of autosomal dominant familial Mediterranean fever. Q J Med 2000; 93:217—221.

Akseintjiev I, Torosyan Y, Samuels J, et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. Am J Hum Genet 1998; 64:949—962.

Tcherneitchko D, Legembre M, Cazenove C, et al. The E148Q MEVF allele is not implicated in the development of familial Mediterranean fever. Hum Mutat 2003; 22:339—340.

Topaloglu R, Ozatkin F, Yilmaz E, et al. E148Q is a disease-causing MEVF mutation: a phenotypic evaluation in patients with familial Mediterranean fever. Ann Rheum Dis 2005; 64:750—752.

A close examination of the clinical features of Turkish patients with the E148Q/ E148Q genotype.

Mindén K, Aganna E, McDermott MF, Zink A. Tumour necrosis factor receptor associated periodic syndrome: new mutations in TNFRSF1A, ancestral origin, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001; 69:301—314.

Lamprecht P, Mooisig F, Adam-Klages S, et al. Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 2005; 64:1518—1520.

First report of panniculitis in TRAPS.

Trost S, Rosé C. Myocarditis and sacroiliitis: 2 previously unrecognized manifestations of tumor necrosis factor receptor associated periodic syndrome. J Rheumatol 2005; 32:175—177.

This paper reports two new manifestations in an African American patient with the P46L mutation and severe TRAPS.

Akseintjiev I, Galon J, Soares M, et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2005; 79:235—237.

This paper reports a P46L allele frequency of approximately 10% in west African populations, suggesting that this substitution frequently is not associated with symptoms of TRAPS. Additional genes that may affect the phenotype associated with this variant remain to be identified.

Wanderer AA, Hoffman HM. The spectrum of acquired and familial cold-induced urticaria/urticaria-like syndromes. Immunol Allergy Clin North Am 2005; 20:453—469.

A comprehensive review of the urticarias, including detailed clinical and diagnostic features.

Neven B, Callebaut I, Prieur AM, et al. Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory syndromes CINCA/NOMID, MWS, and FCU. Blood 2004; 103: 2809—2815.

This paper expands the mutational spectrum of CIAS1 responsible for CAPS and predicts a three-dimensional model of cryopyrin indicating a critical region for its intermolecular contacts that would be affected by the majority of CIAS1 mutations.
A German family with MWS, manifested by arthritis, hearing loss, and amyloidosis, MWS patients with anakinra.

mevalonate kinase polymorphisms and splice site variants.

ical manifestation of autoinflammatory diseases and reports a series of new complex cases with coexistence of mutations in different autoinflammatory genes.

by cold and without urticaria.

Atypical presentation of FCAS with recurrent fever and inflammation not induced by cold and without urticaria.

31 Aganna E, Zeharia A, Hitman GA, McDermott MF, Aganna E, Hitman GA, McDermott MF, Houten SM, McDermott MF, et al. Hyper IgD syndrome or periodic fever syndrome or hyper-IgD and periodic fever syndrome, in the Netherlands. Eur J Hum Genet 2003; 11:1198—200.

32 Busbaum JN. The systemic amyloidoses. Curr Opin Rheumatol 2003; 15:67—75.

33 Haas N, Küster W, Zuberer T, Henn BM. Muckle-Wells syndrome: clinical and histological skin findings compatible with cold urticaria in a large kindred. Br J Dermatol 2004; 151:99—104.

A German family with MWS, manifested by arthritis, hearing loss, and amyloidosis, but with cold-induced urticaria.

34 Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50:607—612.

Report of the overlapping clinical features of CAPS and an effective treatment of MWS patients with anakinra.

35 Hentgen V, Despert V, Leprêtre AC, et al. Intrafamilial variable phenotypic expression of a CIAS1 mutation: from Muckle-Wells to chronic infantile neu- rologic, cutaneous, and articular syndrome. J Rheumatol 2003; 30:747—751.

36 Pörksen G, Lohse P, Rösen-Wolff A, et al. Periodic fever, mild arthralgias, and reversible moderate and severe organ inflammation associated with the V198M mutation in the CIAS1 gene in three German patients: expanding phenotype of CIAS1 related autoinflammatory syndrome. Eur J Haematol 2004; 73:123—127.

Atypical presentation of FCAS with recurrent fever and inflammation induced by cold and without urticaria.

37 Frenkel J, van Kempen M, Kuis W, van Amstel H. Variant chronic infantile neuro-logic, cutaneous, articular syndrome due to a mutation within the leucine-rich repeat domain of CIAS1. Arthritis Rheum 2005; 50:2719—2720.

A mutation in the LRR of CIAS1 presenting with joint symptoms and sensorineural hearing loss but without fever.

38 Dodé C, de Du N, Cuisset L, et al. New mutations of CIAS1 that are responsi-ble for Muckle-Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes. Am J Hum Genet 2002; 70:1498—1506.

39 Aganna E, Martinon F, Hawkins PN, et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent febrile episodes, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002; 46:2445—2452.

40 Årstedeg J, Åldea A, Modesto C, et al. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. Arthritis Rheum 2004; 50:4045—4050. This report adds further evidence that the V198M mutation spans the FCAS and MWS phenotypes and that the D303N and T348M mutations span the MWS and NOMID/CINCA phenotypes.

41 Rösen-Wolff A, Quetsch J, Schröder H, et al. Two German CIINCA (NOMID) patients with different clinical severity and response to anti-inflammatory treat-ment. Eur J Haematol 2003; 71:215—219.

42 Stojanov S, Lohse P, Lohse P, et al. Molecular analysis of the MVK and TNFRSF1A genes in patients with a clinical presentation typical of the hyper-immunoglobulinemia D with periodic fever syndrome: a low-penetrance variant in a heterozygous carrier possibly influences the phenotype of hyperimmunoglobulinemia D with periodic fever syndrome or vice versa. Arthritis Rheum 2004; 50:1981—1988.

This paper investigates the MVK and TNFRSF1A genotype influence on the clinical manifestation of autoinflammatory diseases and reports a series of new mevalonate kinase polymorphisms and splice site variants.

43 Hoffmann F, Lohse P, Stojanov S, et al. Identification of a novel mevalonate kinase gene mutation in combination with the common MVK V377I substitution and the low-penetrance TNFRSF1A R92Q mutation. Eur J Hum Genet 2005; 13:510—512.

Report of a complex autoinflammatory case with surprisingly mild and atypical clinical features.

44 Arkwright PD, McDermott MF, Houten SM, et al. Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol 2002; 130:484—488.

45 Stojanov S, Lohse P, McDermott MF, et al. Periodic fever due to a novel TNFRSF1A mutation in a heterozygous Chinese carrier of MEVF E148Q. Rheumatology 2004; 43:526—527.

Report expanding the ethnic distribution of TRAPS and underlying the issue of complex cases with coexistence of mutations in different autoinflammatory genes.

46 Booth DR, Lachmann HJ, Gillmore JD, et al. Prevalence and significance of the familial Mediterranean fever gene mutation encoding pyrin Q148. Q J Med 2001; 94:527—531.

47 Houten SM, van Woerden CS, Wijburg FA, et al. Carrier frequency of the V377I (1129G>A) MVK mutation, associated with Hyper-IgD and periodic fever syndrome, in the Netherlands. Eur J Hum Genet 2003; 11:1198—200.

48 Duzova A, Bakkaloglu A, Besbas N, et al. Role of A-SAA in monitoring sub-clinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 2003; 21:509—514.

49 Notarnicola C, Didelot MN, Seguret F, et al. Enhanced cytokine mRNA levels in attack-free patients with familial Mediterranean fever. Genes Immun 2002; 3:43—45.

50 Bentancur AG, Naveh N, Lancer J, et al. Urine leukotriene B4 in familial Mediter-ranean fever. Clin Exp Rheumatol 2004; 22(Suppl 34):S56—S58.

51 Persistent elevations in urinary leukotriene B4 between FMF attacks, suggesting ongoing biochemical inflammation.

52 Körüklü Ş, Öztiş M, Balci M, et al. Interferon-gamma levels during and between attacks in FMF, comparable in colchicine-treated and untreated groups.

53 Cañeneuve C, Sarkisian T, Pechoux C, et al. MEVF gene analysis in Armenian patients with familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype: genetic and therapeu-tic implications. Am J Hum Genet 1999; 65:88—97.

54 Brik R, Shinawi M, Kepten I, et al. Familial Mediterranean fever: clinical and genetic characterization in a mixed pediatric population of Jewish and Arab patients. Pediatrics 1999; 103:e70.

55 Gershoni-Baruch R, Brik R, Shinawi M, et al. The differential contribution of MEVF mutant alleles to the clinical profile of familial Mediterranean fever. Eur J Hum Genet 2002; 10:145—149.

56 Shahat M, Magal N, Shohat T, et al. Phenotype-genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis. Eur J Hum Genet 1998; 7:287—292.

57 Mansour I, Delagave V, Caazeneuve C, et al. Familial Mediterranean fever in Lebanon: mutation spectrum, evidence for cases in Maronites, Greek Ortho-doxes, Greek Catholics, Syriacs and Chites and for an association between amyloidosis and M694V and M694I mutations. Eur J Hum Genet 2001; 9:51—55.

58 Tuncu M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005; 84: 1—11.

This paper describes demographic, clinical, and genetic features of the largest series of Turkish patients with FMF.

59 Tekin M, Yağlınkaya F, Çakar N, et al. MEVF mutations in multiplex families with familial Mediterranean fever: is a particular genotype necessary for amyloidosis? Clin Genet 2000; 57:430—434.

60 Yağlınkaya F, Tekin M, Çakar N, et al. Familial Mediterranean fever and sys-temic amyloidosis in untreated Turkish patients. Q J Med 2000; 93:681— 684.

61 Cañeneuve C, Ariapetyan H, Papin S, et al. Identification of MEVF indepen-dent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet 2000; 67:1136—1143.

62 Gershoni-Baruch R, Brik R, Zack N, et al. The contribution of genotypes at the MEVF and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 2003; 48:1149—1155.

63 Bakkaloglu A, Duzova A, Ozen S, et al. Influence of serum amyloid A (SAA1) and SAA2 gene polymorphisms on renal amyloidosis, and on SAA/C-reactive protein values in patients with familial Mediterranean fever in the Turkish population. J Rheumatol 2004; 31:1139—1142.

This study supports a role for the SAA1 gene in the susceptibility to amyloidosis in Turkish FMF patients.

64 Medlej-Hashim M, Delagave V, Chouery E, et al. Amyloidosis in familial Mediter-ranean fever patients: correlation with MEVF genotype and SAA1 and MICA polymorphisms effects. BMC Med Genet 2004; 5:4.

In this study of Arab FMF patients, systemic amyloidosis was associated with the M694V MEVF mutation and the SAA1 gene, but not with variation in MICA.
Fidder HH, Chowers Y, Lidar M, Cattan D, Notarnicola C, Molinari N, FMF-associated mutations may be implicated in the pathogenesis of Behcet's disease. Arthritis Rheum 2004; 50:2966—2969.

First report of amyloidosis in a patient with HIDS.

Poirer O, Nicaud V, Gariepy J, et al. Polymorphism R92Q of the tumour necrosis factor receptor 1 gene is associated with myocardial infarction and carotid intima-media thickness: the ECTIM, AXA, EVA and GENIC studies. Eur J Hum Genet 2004; 12:213—218.

This paper outlines a possible risk of TNFRSF1A R9Q allele carriers for atherosclerosis.

Aganna E, Hawkins PN, Ozen S, et al. Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun 2004; 5:289—293.

The E148Q variant of MEFV and the R92Q variant of TNFRSF1A may contribute to amyloidosis susceptibility in a small number of patients.

Cattan D, Notarcolica C, Molinari N, et al. Inflammatory bowel disease in non-Ashkenazi Jews with familial Mediterranean fever. Lancet 2000; 355: 378—379.

Fidder HH, Chowrens Y, Lidar M, et al. Crohn disease in patients with familial Mediterranean fever. Medicine (Baltimore) 2002; 81:411—416.

Karban A, Dagan E, Elakim R, et al. Prevalence and significance of mutations in the familial Mediterranean fever gene in patients with Crohn’s disease. Genes Immun 2005; 6:134—139.

Analysis of MEFV mutations in an Israeli cohort of Crohn’s disease patients. Although MEFV mutations were not associated with an increased risk of Crohn’s disease, the E148Q variant was associated with periapical lesions.

Toutou I, Magne X, Molinari N, et al. MEFV mutations in Behcet’s disease. J Med Genet 2005; 42:271—272.

Schwartz T, Langevitz P, Zemer D, et al. Behcet’s disease in familial Mediterranean fever: characterization of the association between the two diseases. Semin Arthritis Rheum 2000; 29:286—295.

Imirzalioglu N, Dursun A, Tastan B, et al. MEFV gene is a probable susceptibility gene for Behcet’s disease. Scand J Rheumatol 2005; 34:56—58.

A survey of MEFV mutations in a Turkish Behcet’s disease cohort suggests that FMF-associated mutations may be implicated in the pathogenesis of Behcet’s disease.

Ozen S, Bakkaloglu A. C reactive protein: protecting from lupus in familial Mediterranean fever. Ann Rheum Dis 2005; 64:786—787.

Horuchi T, Tsukamoto H, Mitoma H, et al. Novel mutations in TNFRSF1A in patients with typical tumor necrosis factor receptor-associated periodic syndrome and with systemic lupus erythematosus in Japanese. Int J Mol Med 2004; 14:813—818.

Richards N, Schaner P, Diaz A, et al. Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J Biol Chem 2001; 276:39320—39329.

Hiller S, Kohl A, Fiozto F, et al. NMR structure of the apoptosis- and inflammation-related NALP pyrin domain. Structure 2003; 11:1199—1205.

Liepinsh E, Barbars R, Dahl E, et al. The death-domain fold of the ASC PYRIN domain, presenting a basis for PYRIN/PYRIN recognition. J Mol Biol 2003; 323:1155—1163.

Steinhil C, Reed JC. The PYRIN connection: novel players in innate immunity and inflammation. J Exp Med 2004; 200:551—558.

An excellent review discussing the PYRIN family of proteins and their molecular interactions.

Chae JJ, Komarow HD, Cheng J, et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 2003; 11:591—604.

Dowds TA, Masumoto J, Chen FF, et al. Regulation of cryopyrin/Pyrp1 signaling by pyrin, the familial Mediterranean fever gene product. Biochem Biophys Res Commun 2003; 302:575—580.

Masumoto J, Dowds TA, Schaner P, et al. ASC is an activating adaptor for NF-kappa B and caspase-B-dependent apoptosis. Biochem Biophys Res Commun 2003; 302:767—773.

Gumucio DL, Diaz A, Schaner P, et al. Fire and ICE: the role of pyrin domain-containing proteins in inflammation and apoptosis. Clin Exp Rheumatol 2002; 20(Suppl 26):S45—S53.
Excellent treatment trial of anakinra in FCAS patients.

First report of a NOMID / CINCA patient with favorable response to anakinra.

MWS patients with anakinra.

Report of the overlapping clinical features of CAPS and an effective treatment of Frenkel J, Rijkers GT, Mandey SH, 109 methylglutaryl—coenzyme A reductase inhibition with simvastatin in HIDS patients.

•

•

•

•

•

•

•

109 MWS patients with anakinra.

Report of the overlapping clinical features of CAPS and an effective treatment of Frenkel J, Rijkers GT, Mandey SH, 109 methylglutaryl—coenzyme A reductase inhibition with simvastatin in HIDS patients.

•

•

•

•

•

•

109 Frenkel J, Rijkers GT, Mandey SH, et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Adv Pediatr 2000; 47: 1–53.

108 Simon A, Drew E, van der Meer JW, et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004; 75:476—483.

Clinical trial investigating the anti-inflammatory properties of 3′-hydroxy-3′-methylglutaryl—coenzyme A reductase inhibition in HIDS patients.

108 Frenkel J, Rijkers GT, Mandey SH, et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Adv Pediatr 2000; 47: 1–53.

109 Houten SM, Frenkel J, Rijkers GT, et al. Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet 2002; 11:3115—3124.

111 Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364:1779—1785.

Excellent clinical trial of anakinra in FCAS patients.

Houten SM, Frenkel J, Rijkers GT, et al. Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet 2002; 11:3115—3124.

111 Frenkel J, Rijkers GT, Mandey SH, et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Adv Pediatr 2000; 47: 1–53.

109 Houten SM, Frenkel J, Rijkers GT, et al. Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet 2002; 11:3115—3124.

111 Frenkel J, Rijkers GT, Mandey SH, et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Adv Pediatr 2000; 47: 1–53.

108 Simon A, Drew E, van der Meer JW, et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004; 75:476—483.

Clinical trial investigating the anti-inflammatory properties of 3′-hydroxy-3′-methylglutaryl—coenzyme A reductase inhibition in HIDS patients.

108 Frenkel J, Rijkers GT, Mandey SH, et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Adv Pediatr 2000; 47: 1–53.

109 Houten SM, Frenkel J, Rijkers GT, et al. Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet 2002; 11:3115—3124.

111 Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364:1779—1785.

Excellent clinical trial of anakinra in FCAS patients.

111 Frenkel J, Rijkers GT, Mandey SH, et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Adv Pediatr 2000; 47: 1–53.

109 Houten SM, Frenkel J, Rijkers GT, et al. Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet 2002; 11:3115—3124.

111 Frenkel J, Rijkers GT, Mandey SH, et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Adv Pediatr 2000; 47: 1–53.

108 Simon A, Drew E, van der Meer JW, et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004; 75:476—483.

Clinical trial investigating the anti-inflammatory properties of 3′-hydroxy-3′-methylglutaryl—coenzyme A reductase inhibition in HIDS patients.

108 Frenkel J, Rijkers GT, Mandey SH, et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Adv Pediatr 2000; 47: 1–53.

109 Houten SM, Frenkel J, Rijkers GT, et al. Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet 2002; 11:3115—3124.

111 Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364:1779—1785.

Excellent clinical trial of anakinra in FCAS patients.

111 Frenkel J, Rijkers GT, Mandey SH, et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Adv Pediatr 2000; 47: 1–53.

109 Houten SM, Frenkel J, Rijkers GT, et al. Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet 2002; 11:3115—3124.

111 Frenkel J, Rijkers GT, Mandey SH, et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Adv Pediatr 2000; 47: 1–53.